Trial record 8 of 16 for:    Bronchitis | Open Studies | NIH, U.S. Fed

Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2013 by Brigham and Women's Hospital
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Edwin K. Silverman, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT01177618
First received: August 6, 2010
Last updated: December 13, 2013
Last verified: December 2013
  Purpose

Chronic obstructive pulmonary disease (COPD) is often caused by cigarette smoking, but genetic predisposition also influences COPD susceptibility. The purpose of this study is to identify genetic factors that predispose some individuals to develop COPD.


Condition
Chronic Obstructive Pulmonary Disease

Study Type: Observational
Study Design: Observational Model: Family-Based
Time Perspective: Cross-Sectional
Official Title: Genetic Epidemiology of Severe, Early-Onset Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:


Further study details as provided by Brigham and Women's Hospital:

Primary Outcome Measures:
  • No Primary Outcome [ Designated as safety issue: No ]
    Since this is an observational study, there are no primary outcomes


Biospecimen Retention:   Samples With DNA

DNA, Serum, Plasma, Buccal Brushings, and Urine


Estimated Enrollment: 2000
Study Start Date: July 1994
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts
Probands
Severe, early-onset COPD subjects that bring the family into the study
Relatives
Relatives of early-onset COPD probands, including first-degree relatives (parents, siblings, and children), second-degree relatives (aunts, uncles, grandparents, half-siblings), spouses, and other affected individuals.

Detailed Description:

Chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in the United States, affects millions of people around the world. COPD, which can include both emphysema and chronic bronchitis, affects the lungs making it very difficult to breathe. Cigarette smoking is the most common risk factor for developing COPD; however, only 15% to 20% of smokers develop COPD in their lifetimes. The onset of COPD also varies greatly from person to person; while some people do not develop respiratory symptoms until later in life, there are others who develop severe COPD at a very early age. Prior research has led to the discovery of the alpha-1 antitrypsin protein deficiency in association with COPD development. This discovery has generated further interest toward studying other genetic factors which may also affect an individual's likelihood of developing COPD. Therefore, the purpose of the Boston Early-Onset COPD study is to gain a better understanding of COPD risk factors in order to establish new possible methods of treatment for people affected by COPD.

For this study we are enrolling individuals affected with severe COPD (52 years old or younger with an FEV1 < 40%) and their family members. Each participant will attend one study visit that involves a respiratory questionnaire, a breathing test, and blood draw. This visit can be completed at the participant's home, in the hospital, or by long distance data collection (phone interview, local breathing tests, and local blood draw with mailed samples), whichever is preferred.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Severe, early-onset COPD subjects and their relatives

Criteria

Inclusion Criteria for Early-Onset COPD Probands:

  • Early onset of COPD in individuals younger than 53 years old
  • Spirometry results that are indicative of severe COPD (FEV1 < 40% predicted)
  • Physician-diagnosed COPD

Exclusion Criteria for Early-Onset COPD Probands:

  • Severe alpha-1 antitrypsin deficiency
  • Other chronic lung diseases in participants with COPD (except asthma)
  • Pregnant
  • Any previous lung surgery including lung transplant or lung reduction volume surgery (LVRS); unless prior Pulmonary Function Tests are available
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01177618

Contacts
Contact: Edwin K. Silverman, M.D., Ph.D. 617-525-2128 ed.silverman@channing.harvard.edu

Locations
United States, Massachusetts
Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Josh Medeiros    617-525-2075    rejtm@channing.harvard.edu   
Contact: Sandra Melanson    617-525-2128    redra@channing.harvard.edu   
Principal Investigator: Edwin K. Silverman, M.D., Ph.D.         
Sub-Investigator: Dawn L. DeMeo, M.D.         
Sub-Investigator: Craig P. Hersh, M.D.         
Sponsors and Collaborators
Brigham and Women's Hospital
  More Information

Publications:

Responsible Party: Edwin K. Silverman, Professor of Medicine, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT01177618     History of Changes
Obsolete Identifiers: NCT00106444
Other Study ID Numbers: 1437, R01HL075478, R01HL113264
Study First Received: August 6, 2010
Last Updated: December 13, 2013
Health Authority: United States: Federal Government

Keywords provided by Brigham and Women's Hospital:
Chronic Obstructive Pulmonary Disease
COPD
Emphysema
Chronic Bronchitis
Genetics
Association Studies

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 25, 2014